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Summary.-The effect of renal failure on melphalan pharmacology and toxicity
has been poorly understood. Such information is of interest because melphalan is the
most commonly used anticancer drug in the treatment of multiple myeloma, which
is frequently associated with renal failure. We have studied the disposition and
marrow toxicity of parenteral melphalan in dogs before and after induction of renal
failure with subtotal nephrectomy. The surgical procedure decreased the creatinine
clearance by an average of 62% (P=0-001). The lowest neutrophil counts following
i.v. melphalan (1 mg/kg) averaged 4.9 x 103/mm3 pre-nephrectomy and 0-9 x 103/mm3
post-nephrectomy, respectively (P=0.002). The mean lowest recorded platelet counts
after melphalan (1 mg/kg) were 115 x 103/mm3 in the pre-nephrectomized dogs, and
9-7 x 103/mm3 in those who had been nephrectomized (P=0.002). Following nephrect-
omy, i.v. melphalan's terminal-phase plasma half-life and renal clearance were both
raised (P=0.02) to 75%O over pre-nephrectomy values. These studies show that i.v.
melphalan-induced myelosuppression is markedly increased and its plasma elimina-
tion and renal clearance significantly decreased in the presence of renal dysfunction
in dogs. These data suggest that parenteral melphalan's starting dose be decreased
by at least 50%o when used in myeloma patients with renal failure.
MELPHALAN continues to be one of the
most important anticancer drugs in the
treatment of multiple myeloma (Speed et
al., 1964; Alexanian et al., 1968; Bergsagel
et al., 1979). As many as one third of all
myeloma patients will have severely re-
duced renal function as a result of renal
tubular damage from paraprotein deposi-
tion and/or the toxic effects of hyper-
calcaemia (Kayle & Bayrd, 1976). Al-
though the alkylating agent melphalan is
commonly used in myeloma patients with
renal failure, it is not known whether renal
dysfunction alters its pharmacokinetics or
marrow toxicity. Speed et al. (1964)
suggested that the rate of melphalan
urinary excretion might be decreased in
the presence of renal failure. We have
studied the disposition and marrow
toxicity of melphalan in dogs before and
after surgically induced renal failure. The
results of these studies suggest that severe
renal dysfunction can slow the plasma and
renal clearance ofmelphalan and markedly
increase neutropenia and thrombocyto-
penia.
MATERIALS ANI) METHODS
Dogs.-Eight male mongrel dogs, weighing
17-23 kg, which had been previously quaran-
tined for 2-4 weeks in the vivarium, were
used. The dogs were without evidence of
infection and were not given other drugs
during the entire duration of the melphalan
studies. Baseline BUN, serum creatinine, and
24h urinary creatinine clearance were meas-
ured in each of the animals, and were re-
measured after the surgical induction ofrenal
dysfunction.
An indwelling 16-gauge catheter was inser-
ted into a superficial leg vein. Melphalan
(1 mg/kg body weight) wAas injected i.v. over
about 1 min, followed by 10 ml normalRENAL DYSFUNCTION AND MELPHALAN TOXICITY
saline. The catheter was thoroughly flushed
several times with blood after melphalan
injection and blood samples were taken
through this catheter.
Surgical procedures.-Four to six weeks
after the first dose of melphalan, azotemia
was produced by unilateral total nephrectomy
and contralateral partial nephrectomy.
Gierke et al., 1978. The right kidney was
removed through a midabdominal incision.
Branches of the contralateral renal artery
were ligated and the extent of necrosis was
determined by observing ischemia on the
surface ofthe kidney until about one quarter
of the remaining kidney remained viable. If
the arterial branching at the renal pelvis
was not sufficiently extensive to accomplish
this, part of the kidney was ligated with
number 0 chromic gut after the capsule was
lifted from the ligated segment of renal
parenchyma. The capsule was sewn over the
ligated portion of the kidney parenchyma to
control bleeding. The experimental protocol
previously described (i.e., melphalan, 1 mg/kg
i.v.) was repeated when serum electrolytes,
creatinine and blood urea nitrogen (BUN) had
stabilized.
Drug formulation, dosage and administra-
tion.-Melphalanpowder (Alkeran, Burroughs
Wellcome Co., Research Triangle Park, NC)
was stored in powder form at -4C until
use. Immediately before administration, 1 ml
of Burroughs Wellcome acid ethanol was
added to 100 mg melphalan, which after
dissolution was further diluted with 9 ml of
Burroughs Wellcome brand diluent (i.e.,
K2HPO4 in propylene glycol and water) and
placed on ice.
Blood and urine sampling.-Blood samples
(10 ml) were collected in tubes containing
100 iu of heparin. Blood samples were taken
just before the start of therapy and at 5, 15,
30, 45 and 60 min, and 2, 3, 4, 6, 8 and 24 h
after drug injection. They were placed on ice
for a short period before refrigerated centri-
fugation at 2000 rev/min for 10 min. The
separated plasma samples were then stored
at -20°C. Fractional urine collection, using
size-8 straight, disposable catheters, were
taken for the first 6 h after drug injection.
The dogs were then placed in metabolic
cages and urine was collected for 24h periods
up to 3 days. The urine was drained from
the bottom ofthe cage into collection bottles.
The urinary volume of each 24h period was
measured and aliquots were stored at -20°C
in sterile containers to which concentrated
HCI had been added as a preservative.
Blood counts and serum chemistries.-
Standard procedures were used to measure
renal function and complete blood counts on
the dogs at weekly intervals to evaluate renal
status and melphalan's haemopoietic toxicity.
Melphalan assays.-Melphalan was assayed
in biological fluids using high-pressure liquid
chromatography (HPLC) as previously des-
cribed by Chang et al. (1978).
Data analysis.-The concentrations of mel-
phalan in plasma were averaged to obtain
the combined data for the pre- and post-
nephrectomy groups, respectively. Each dog's
data and the combined data for each group
were then fitted to a multiexponential equa-
tion using a nonlinear-regression computer
program, NONLIN (Metzler, 1969). The
half-lives and area under the plasma decay
curve (C xT) were calculated from the
parameters generated by curvefitting (Alberts
et al., 1979a). The melphalan renal clearances
(Qr) were calculated from:
Q = total urinary excretion
Qr= CxT
for each dog and then averaged for both pre-
and post-nephrectomy groups.
To compare the effect of nephrectomy on
melphalan pharmacokinetics, a two-tailed,
unpaired Student's t test was used to compute
the P values for the important parameters.
A P of <0 05 was taken as statistically
significant.
RESULTS
Renal status
The BUN, serum creatinine and 24h
urinary creatinine clearance before
nephrectomy for 8 dogs averaged 19 9 + 5-3
mg/100 ml, 1 0+0 02 mg/100 ml, and
41-2 + 2-7 ml/min, respectively (Table I).
After surgical induction of renal failure,
BUN increased more than 2-fold, serum
creatinine more than 3-fold, and 24h
urinary creatinine clearance decreased to
less than half (Table I). For each labora-
tory test pre- and post-nephrectomy
values were statistically different, as
shown in Table I.
Melphalan-induced myelosuppression
In the dogs with normal renal function,
melphalan (1 mg/kg i.v.) produced the
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TABLE I.-Measurements of renalfunction
indogs before and after surgically induced
renalfailure (mean+ s.e.)
Creatinine
BUN Creatinine clearance
(mg%) (mg%) (ml/min)
Pre-nephrectomy 19-9+5-3 1 0_0-02 41-2_2-7
Post-nephrectomy 49-8 + 5-3 3-2 + 0-41 15-7 + 7-6
P 0 004 0.001 0 001
following average nadir blood counts on
Day 14, as shown in Table II: WBC
5*1 + 1*5 x 103/mm3; neutrophils 4X9 + 0 7
x 103/mm3; and platelet count 115+23
x 103/mm3. There was no evidence that
repeated doses of i.v. melphalan (i.e.
1 mg/kg) at monthly intervals for up to
3 consecutive courses induced cumulative
marrow damage in either normal or
nephrectomized dogs. After the surgical
induction ofrenal dysfunction, i.v. melph-
alan caused a more than 2-fold reduction
in the average nadir white cell count, a
more than 5-fold reduction in the mean
nadir neutrophil count and a more than
11-fold reduction in the mean nadir plate-
let count. For neutrophils and platelets,
pre- and post-nephrectomy values were
statistically different (Table II). After
nephrectomy, the neutrophil and platelet
count nadirs were on Day 8 (i.e. 6 days
TABLE II.-Melphalanmyelotoxicityfollow-
ing 1 mg/kg i.v. in dogs before and after
surgically induced renal failure (mean +
s.e.)
Pre-nephrectomy
Post-nephrectomy
p
WBC
(x 103/
mm3)
5.1 +1.5
2-0+04
0-08
Neutro- Plate-
phils lets
( x 103/ ( x 103/
mm3) mm3)
4-9+07 115-0+23-0
0 9+0-2 9-7+3-0
0 001 0-002
before the pre-nephrectomy drug-induced
nadirs).
PHARMACOKINETIC PARAMETERS
Melphalanplasma kinetics
Prior to the surgical induction of renal
dysfunction, the normal dogs had a
melphalan ti4 of 435 + 31 min and an
average C x T of 51b8 .t-g.min/ml (Table
III). Afterrenaldysfunction the melphalan
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FIG. 1.-Melphalan (HPLC) plasma-dis-
appearance curves before and after the
induction of renal failure in dogs. Data
points represent the average of the mel-
phalan plasma concentration at each time
point for up to 8 dogs. Lower curve (0)
dogs prior to nephrectomy. Upper curve
(0) nephrectomized dogs.
TABLE III.-Pharmacokinetics of i.v. melphalan (HPLC) before and after surgically
induced renalfailure in dogs
Pre-nephrectomy
Post-nephrectomy
p
Plasma Urine
t
oc t XB 24h urinary Renal
i -
C x T excretion clearance
(min) (min) (pg.min/ml) (%) (ml/min)
4-5+2-0 43-5+3-1 51-8 4-6+0 9 23-6+3 0
4-725 76-2 + 21-9 81-0 3-1 +0 5 13-2 + 2-2
Not sig. 0-017 Notsig. 0 14 0-02
* C x T=area under the plasma disappearance curve.
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plasma t./3 was 76-2 + 12-9 min and aver-
age C x T, 81 jug.min/ml. Melphalan's
plasma tI, was significantly prolonged
(P= 0-017) when computed from only
terminal-slope data.
Fig. 1 shows the plasma disappearance
curves for melphalan (1 mg/kg i.v. bolus)
before and after surgical induction ofrenal
dysfunction. Note that the upper curve is
that associated with melphalan given to
dogs with renal dysfunction.
Urinary excretion and clearance data
Fig. 2 shows the curves describing the
rate of urinary excretion of melphalan
(1 mg/kg i.v. bolus) in dogs before and
after the surgical induction of renal dys-
function. Markedly lower melphalan con-
centrations were seen in the dogs with
renal impairment at 10-64 h after melph-
alan administration. Although melphalan's
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FiG. 2.-Melphalan (HPLC) urinary excretion
rates before and after the induction of
renal failure in dogs. Data points represent
the average melphalan urinary concentra-
tions for up to 8 dogs. Lower curve (0)
represents nephrectomized dogs. Upper
curve (0) represents dogs prior to neph-
rectomy.
70
24h urinary-excretion percentage was not
significantly changed, its renal clearance
was statistically significant between pre-
and post-nephrectomy (P= 0 02) (Table
III).
DISCUSSION
We have used a well-standardized dog
model (Gierke et al., 1978) to study the
effect of renal dysfunction on the toxicity
and disposition of melphalan, because it
had not been directly investigated either
in the clinic or in a model system. Furner
et al. (1977) have previously described the
pharmacokinetics of i.v. melphalan in the
dog. Their melphalan plasma disappear-
ance and urinary excretion data are simi-
lar to those we observed in our study dogs
before nephrectomy. After the surgical
induction of renal dysfunction there was
a 75% rise in melphalan's terminal-phase
plasma disappearance and renal clearance.
These statistically significant changes in
drug disposition were associated with a
5-fold reduction in the mean nadir neutro-
phil count and an 11-fold reduction in the
mean nadir platelet count. These data
suggest that the initial dose of parenteral
melphalan should be markedly reduced in
patients with severe renal failure.
Unfortunately, our dog model cannot
be used to determine exact dose adjust-
ments for i.v. melphalan in patients with
reduced renal function. In the face of a
drug-induced severe or life-threatening
neutropenia (i.e. < 500 to 1000/mm3
respectively) or thrombocytopenia (i.e.
< 25,000-50,000/mm3) the subsequent
dose of the responsible drug is usually
reduced by at least 50%. A reasonable
clinical guideline for i.v. melphalan dosage
adjustment in patients with severe renal
disease would be an initial 50% reduction
of the standard dose, with careful dose
escalation in subsequent courses, as toler-
ated. Such guidelines have been used by
the Cancer and Leukemia Group B in a
randomized study of i.v. bolus melphalan
in myeloma patients who have varying
degrees of renal failure (Corwell, personal
communication).
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We do not recommend a dose reduction
of orally administered melphalan in myel-
oma patients with diminished renal func-
tion. WJe have previously shown that there
is marked variability of systemic avail-
ability of melphalan after oral administra-
tion (Alberts et al., 1979b), and the oral
route would tend to minimize the adverse
marrow effects. When the parenteral route
is used, however, the suggested dose
a(djustments should be made.
Supported by research grants CA-17094 and
T32-GM107533 from the National Institutes of
Health, U.S. Public Health Seivice, Department of
Health, Education, a(ld Welfare, Bethesda, MD;
Buirroughs Wellcome Co., Research Triangle Park,
NC; and the Phi Beta Psi National Sorority, Lima,
OH.
We wish to thanik Dr Klaus Gierke for his surgical
expertise, Dr Sai Y. Chang and Barbara Larcom for
their analytical chemistry expertise, Tom Evans
and Robin Staerkel for their research assistance,
aui(l Dr Sydney E. Salmon for his scientific advice
an(l critical review of this mantuscript.
REFERENCES
ALBERTS, D. S., CHANG, S. Y., CHEN, H.-S.G. &
others (1979(t) Kinetics of iintravenous melphalan.
(Cliot. Phariooacol. Ther., 26, 73.
ALBERTS, D. S., CHANGC, S. Y., CHEN, H.-S.G.,
EVANS, T. L. & AIOON, T. E. (1979b) Oral mel-
phalan kinetics. Cliti. Pharmacol. T'her., 26, 737.
ALEXANIAN, R., BERGSACGEL, D. E., MIGLIORE, P. J.,
VAUGHN, W. K. & HOWE, C. D. (1968) Melphalan
therapy for plasma cell myeloma. Blood, 31, 1.
BERGSAGEL, D., BAILEY, A. J., LANG4LEY, G. H.,
MAICDONALD, R. NT., WHITE, D. F. & MIILLEIR,
A. B. (1979) The chemotherapy of plasma-cell
myeloma and the incidence of acuite leuikemia.
N. Engl. J. Med., 301, 743.
CHANG, S. Y., ALBERTS, D. S., MELNICK, L. R. &
otheis (1978) High-pressure liquicd chromato-
graphic analysis ofmelphalan in plasma. J. Pharne.
Sci., 67, 679.
FlJRNER, R. L., BoRWN, H. K. & DUNCAN, G. (1977)
Pharmacokinetics of absorption, distribution an(I
elimination of melphalan in the dog. Caancer
Treat. Rep., 61, 1637.
GIERKE, K. D., PERRIER, D., MAYERSOHN, AM. &
MARCITS, F. I. (1978) Digoxin disposition kinetics
in (logs before and during azotemia. J. Pharmn.
Exp. 7'herap., 205, 459.
KAYLE, R. A. & BAYRD, E. D. (1976) The Mono-
clonal Gamnnopathies: Multiple M!yelomta anid
Related I)isorders. Springfield: Charles C. Thomas.
p. 91.
METZLER, C. M. (1969) NONLIN: A computer
program for paiameter estimation in nonlinear
situations. Kalamazoo: Upjohn Co. Technical
Report 7292/69/7292/005.
SPEED, D. E., GALTON, D. A. G. & SWAN, A. (1964)
Melphalan in the treatment of myelomatosis.
Br. Med. J., 1, 1664.